Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dova Pharmaceuticals Inc.DOVA · Entity 153784 | Director · President & CEO | August 14, 2018 | August 15, 2018 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director · See Remarks | February 02, 2026 | February 04, 2026 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dova Pharmaceuticals Inc.
Report date August 14, 2018 · Filed August 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 21,700 |
Reported balance
After 2018-08-14 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-08-14 · Purchase · Acquired 21,700 · Balance 21,700 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.65 - 23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. F2: The reportable securities are owned directly by Alexander C. Sapir Revocable Trust (the "Trust"). The Reporting person is the trustee of the Trust. |
| Common StockSEC Table I · non-derivative | Direct | 46,909 |
Reported balance
Holding disclosure · report date 2018-08-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 46,909 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.65 - 23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
F2: The reportable securities are owned directly by Alexander C. Sapir Revocable Trust (the "Trust"). The Reporting person is the trustee of the Trust.
Fulcrum Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2036-02-01 | Direct | 650,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 650,000 · Balance 650,000 F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,750 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 3,750 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-19 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock option - Right to Buy · Derivative | 650,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001193125-26-037572 · ownership.xml · derivative · entry 1 Sapir Alex · CIK 0001709415 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock option - Right to Buy · Derivative | 582,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-25-009816 · ownership.xml · derivative · entry 1 Sapir Alex · CIK 0001709415 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 582,000 Underlying: Common Stock · 582,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2025 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2025, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 12:00 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionStock option - Right to Buy · Derivative | 150,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000950170-24-081949 · ownership.xml · derivative · entry 2 Sapir Alex · CIK 0001709415 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,280,400 Underlying: Common Stock · 150,000 shares Expires 2033-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. F2 · derivative.exercise_date: This option was granted on May 12, 2023 and vested 25% on the first anniversary of the vesting commencement date of May 12, 2023. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 12:00 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | Exercise / conversionCommon Stock | 150,000 | $3.27 | $490,500.00 |
DisclosureSEC source: 0000950170-24-081949 · ownership.xml · nonDerivative · entry 1 Sapir Alex · CIK 0001709415 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 43,360 | $11.35 | $492,027.60 |
DisclosureSEC source: 0000950170-24-025933 · ownership.xml · nonDerivative · entry 1 Sapir Alex · CIK 0001709415 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,360 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.50, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:17 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-23-000029 · wf-form4_168452741659043.xml · derivative · entry 2 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:17 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001169245-23-000029 · wf-form4_168452741659043.xml · nonDerivative · entry 1 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:45 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-22-000063 · wf-form4_165307950359150.xml · derivative · entry 2 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. F3 · derivative.expiration_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:45 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001169245-22-000063 · wf-form4_165307950359150.xml · derivative · entry 1 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 18:14 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001169245-21-000064 · wf-form4_162284484859159.xml · derivative · entry 1 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 18:39 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 4,909 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001169245-20-000057 · wf-form4_159139675921098.xml · derivative · entry 1 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,909 Underlying: Common Stock · 4,909 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2021 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 18:50 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantEmployee Stock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001169245-20-000030 · wf-form4_158172421148134.xml · derivative · entry 1 Sapir Alex · CIK 0001709415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from February 12, 2020, subject to the reporting person's continued service through each such date. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:27 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | PurchaseCommon Stock | 21,700 | $22.83 | $495,411.00 |
DisclosureSEC source: 0001209191-18-046800 · doc4.xml · nonDerivative · entry 1 Sapir Alex · CIK 0001709415 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 21,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.65 - 23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. F2 · ownership.nature: The reportable securities are owned directly by Alexander C. Sapir Revocable Trust (the "Trust"). The Reporting person is the trustee of the Trust. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 16:32 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,809 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001209191-17-067415 · doc4.xml · derivative · entry 2 Sapir Alex · CIK 0001709415 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,291 Underlying: Common Stock · 26,809 shares Expires 2027-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of Common Stock and shall vest over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on January 3, 2018, and (ii) 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 16:32 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Exercise / conversionCommon Stock | 26,809 | $3.73 | $99,997.57 |
DisclosureSEC source: 0001209191-17-067415 · doc4.xml · nonDerivative · entry 1 Sapir Alex · CIK 0001709415 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 06:44 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | PurchaseCommon Stock | 20,100 | $17.00 | $341,700.00 |
DisclosureSEC source: 0001209191-17-044261 · doc4.xml · nonDerivative · entry 1 Sapir Alex · CIK 0001709415 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.